- Email: [email protected]
5330911 Surfaces having desirable cell adhesive effects
IV
New Patents
5328836 PLASMIDS CONTAINING DNA ENCODING THE AMINO ACID SEQUENCE OF TCF-II AND USE THEREOF Shima Nobuyuki; Higashio Kanji; Nagao Masaya; Oogaki Fumiko; Takaoka Hiroaki; Tsuda Eisuke - Snow Brand Milk Products Co Ltd PCT No. PCT/JP9 l/O0942 Sec. 371 Date Mar. 11, 1992 Sec. 102(e) Date Mar. 11, 1992 PCT Filed Jul. 15, 1991 PCT Pub. No. WO92/01053 PCT Pub. Date Jan. 23, 1992.Plasmids containing DNA encoding the amino acid sequence of a novel glycoprotein (TCF-II) derived from human tibroblasts, transformed cells with the plasmids and production method of rTCF-II using the transformed cells. rTCF-II can be used as a hepatocyte growth factor or a tumor cytotoxic factor.
5328837 HEPATOCYTE GROWTH FACTOR PROTEASE DOMAIN VARIANTS Godowski Paul J; Lokker Melanie - Genentech Inc
Natalie A; Mark
The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.
5330911 SURFACES HAVING DESIRABLE CELL ADHESIVE EFFECTS Hubbell Jeffrey A; Massia Stephen P; Desai Neil - Board of Regents The University of Texas System An absorbed protein-independent cell-adhesive surface is disclosed. The treated surface comprises a chemically derivatized material to which small peptides, having less than 12 amino acid residues and including YIGSR, RGD or REDV amino acid sequence are covalently linked to. The peptides of the present invention include a
terminal glycine amino acid. Tresyl chloride activation of surface hydroxyl moieties provides the active surface sites by which a terminal glycine arm of a selected peptide attaches to form covalent bonds between the substrate and peptide. Peptides high with cell adhesive properties are bound in high efficiency. By way of example, surfaces which may be used in conjunction with the present invention include polymer, metal, and ceramic surfaces. The most preferred polymer surfaces include PHEMA and PET polymer surfaces, with the most preferred glass surfaces being glycophase glass. The present methods also include a pretreatment method which provides hydroxyl moieties to surfaces devoid of readily available hydroxyl moieties. The pretreatment, by way of example, comprises immersion of the surface in a mixture of formaldehyde and acetic acid. Methods of preparing the treated surfaces are also included in the present invention. Also included are surface-treated biomedical implant devices and cell culturing devices. The treated surface promotes an enhanced rate and an enhanced amount of cell adhesion to the surface, independent of media serum concentrations or other absorbed proteins. The treated surfaces of the present invention are thermally stable, reusable, peptide efficient (attached to surface only) and resistant to cell proteolysis. The invention further concerns polymeric substrates with a surface having physically interpenetrating water-soluble polymer chains, and methods for production thereof.
5330993 IMMUNOSUPPRESSIVE COMPOUNDS Armistead David; Boger Joshua S; Meyers Harold V; Saunders Jeffrey; Tung Roger D Vertex Pharmaceuticals Inc This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). bound to this Once protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-tram isomerase (rotamass) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
New Patents
5328836 PLASMIDS CONTAINING DNA ENCODING THE AMINO ACID SEQUENCE OF TCF-II AND USE THEREOF Shima Nobuyuki; Higashio Kanji; Nagao Masaya; Oogaki Fumiko; Takaoka Hiroaki; Tsuda Eisuke - Snow Brand Milk Products Co Ltd PCT No. PCT/JP9 l/O0942 Sec. 371 Date Mar. 11, 1992 Sec. 102(e) Date Mar. 11, 1992 PCT Filed Jul. 15, 1991 PCT Pub. No. WO92/01053 PCT Pub. Date Jan. 23, 1992.Plasmids containing DNA encoding the amino acid sequence of a novel glycoprotein (TCF-II) derived from human tibroblasts, transformed cells with the plasmids and production method of rTCF-II using the transformed cells. rTCF-II can be used as a hepatocyte growth factor or a tumor cytotoxic factor.
5328837 HEPATOCYTE GROWTH FACTOR PROTEASE DOMAIN VARIANTS Godowski Paul J; Lokker Melanie - Genentech Inc
Natalie A; Mark
The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.
5330911 SURFACES HAVING DESIRABLE CELL ADHESIVE EFFECTS Hubbell Jeffrey A; Massia Stephen P; Desai Neil - Board of Regents The University of Texas System An absorbed protein-independent cell-adhesive surface is disclosed. The treated surface comprises a chemically derivatized material to which small peptides, having less than 12 amino acid residues and including YIGSR, RGD or REDV amino acid sequence are covalently linked to. The peptides of the present invention include a
terminal glycine amino acid. Tresyl chloride activation of surface hydroxyl moieties provides the active surface sites by which a terminal glycine arm of a selected peptide attaches to form covalent bonds between the substrate and peptide. Peptides high with cell adhesive properties are bound in high efficiency. By way of example, surfaces which may be used in conjunction with the present invention include polymer, metal, and ceramic surfaces. The most preferred polymer surfaces include PHEMA and PET polymer surfaces, with the most preferred glass surfaces being glycophase glass. The present methods also include a pretreatment method which provides hydroxyl moieties to surfaces devoid of readily available hydroxyl moieties. The pretreatment, by way of example, comprises immersion of the surface in a mixture of formaldehyde and acetic acid. Methods of preparing the treated surfaces are also included in the present invention. Also included are surface-treated biomedical implant devices and cell culturing devices. The treated surface promotes an enhanced rate and an enhanced amount of cell adhesion to the surface, independent of media serum concentrations or other absorbed proteins. The treated surfaces of the present invention are thermally stable, reusable, peptide efficient (attached to surface only) and resistant to cell proteolysis. The invention further concerns polymeric substrates with a surface having physically interpenetrating water-soluble polymer chains, and methods for production thereof.
5330993 IMMUNOSUPPRESSIVE COMPOUNDS Armistead David; Boger Joshua S; Meyers Harold V; Saunders Jeffrey; Tung Roger D Vertex Pharmaceuticals Inc This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). bound to this Once protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-tram isomerase (rotamass) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.